---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018252"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:32:56.488837+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger

## Summary
- Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.
- Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.
- Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.
- R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.
- PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India.

## SEC filing metadata
- accession: 0001493152-25-018252
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/0001493152-25-018252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018252
- JSON: https://secwatch.observer/filing/0001493152-25-018252.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018252.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.